Screener
NeoGenomics NEO Q3 2026 earnings
Reported October 28, 2026 · After market close
Revenue$209.3MBeat by $2.6M
EPS$0.07Beat by $0.01
Revenue estimate$206.7M
EPS estimate$0.06
“Our third-quarter results reinforce that we have the right strategy in place and the right team to execute against it. Clinical revenue growth of 13% continues to showcase the strength of our broad-based testing solutions portfolio, with NGS revenue growing a strong 29% and NGS test volume growing 17%. As our business continues its shift to higher-value, high-margin testing modalities, we see further opportunity to invest into our commercial teams, community channel strength, and product pipeline. At the same time, we expect to reduce complexity across our business through operational excellence initiatives designed to deliver accelerating growth and disciplined margin expansion over the long-term.”
Next report
Date not yet announcedValuation & ratios
Segments
Versus estimates
Revenue
Diluted EPS
FAQ
- When did NeoGenomics report Q3 2026 earnings?
- NeoGenomics (NEO) reported Q3 2026 earnings on October 28, 2026 after market close.
- What were NeoGenomics's Q3 2026 revenue and EPS?
- NeoGenomics reported revenue of $209.3M and eps of $0.07 for Q3 2026.
- Did NeoGenomics beat estimates in Q3 2026?
- Revenue beat the consensus estimate of $206.7M by $2.6M. EPS beat the consensus estimate of $0.06 by $0.01.
- How did NeoGenomics's Q3 2026 results compare year-over-year?
- Compared to the same quarter a year prior, revenue grew 11.4% from $187.8M a year earlier and eps grew 133.3% from $0.03.
- Where can I find NeoGenomics's Q3 2026 SEC filings?
- You can read the 8-K earnings release (0001077183-26-000078) and the 10-Q periodic report (0001077183-26-000079) directly on SEC EDGAR. The filing index links above go to sec.gov.
